Best Up And Coming Companies To Watch In Right Now

With shares of Verizon (NYSE:VZ) trading around $51, is VZ an OUTPERFORM, WAIT AND SEE or STAY AWAY? Let�� analyze the stock with the relevant sections of our CHEAT SHEET investing framework:

T = Trends for a Stock’s Movement

Verizon�is a provider of communications, information and entertainment products and services to consumers, businesses and governmental agencies. It operates in two primary segments: Verizon Wireless and Wireline. Verizon Wireless��communications products and services include wireless voice and data services and equipment sales, which are provided to consumer, business and government customers across the United States. Wireline�� communications products and services include voice, Internet access, broadband video and data, Internet protocol network services, network access, long distance and other services. As consumers and companies strive to communicate at increasing rates, Verizon stands to see a rising profits as a main provider. Look for rising communications, information, and entertainment to drive profits for Verizon.

Best Up And Coming Companies To Watch In Right Now: OXiGENE Inc.(OXGN)

OXiGENE, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics to treat cancer and eye diseases in the United States. It primarily focuses on the development of vascular disrupting agents (VDAs) that disable and destroy abnormal blood vessels, which provide solid tumors a means of growth and survival, as well as associate with visual impairment in various ophthalmological diseases and conditions. The company?s products include ZYBRESTAT, which is in fosbretabulin in anaplastic cancer of the thyroid (FACT) trial?Phase 2/3 study for the treatment of anaplastic thyroid cancer; in fosbretabulin in advanced lung oncology (FALCON) trial?Phase 2 randomized and controlled study to treat non-small cell lung cancer; in Phase 2 Simon two-stage design study for the treatment of platinum-resistant ovarian cancer; and in Phase 2 randomized controlled study to treat platinum-relapsed but platinum sensitive ovarian cancer. Its products also comprise OXi4503 that is in Phase 1 dose-escalation study for the treatment of acute myelogenous leukemia and myelodysplastic syndromes; Phase 1b dose-ranging study to treat solid tumors with hepatic tumor burden; and Phase 1 dose-escalation study for the treatment of refractory solid tumors. In addition, the company?s products consist of ZYBRESTAT, which is in Phase 2 randomized, double-masked, placebo-controlled, single-dose study for proof-of-mechanism study in polypoidal choroidal vasculopathy. OXiGENE has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology, and OXi4503. The company was founded in 1988 and is headquartered in South San Francisco, California.

Advisors' Opinion:

• [By Bryan Murphy]

  In the very short run, OXiGENE Inc. (NASDAQ:OXGN) is overbought and probably due for a setback, not unlike the all the other one-day surges and subsequent pullbacks we've seen from the stock since February of this year. Today's pop from OXGN, however, is quite different than all the rest... this time, it's got a legitimate shot at following through on the upside effort. Ergo, this little biopharma name is actually one of the market's best 'trades' right now.

Best Up And Coming Companies To Watch In Right Now: Quanex Building Products Corporation(NX)

Quanex Building Products Corporation provides engineered products and aluminum sheet products. Its Engineered Products segment produces window and door components for original equipment manufacturers that primarily serve the residential construction and remodeling markets. This segment?s products consist of insulating glass spacer/sealant systems, thin film solar panel sealants, window and patio door screens, aluminum cladding and other roll formed metal window components, thresholds and astragals, moldings, residential exterior products, engineered vinyl and composite patio doors, window profiles and custom window grilles, and trim and architectural moldings in various woods primarily for the home improvement and residential construction markets. The company?s Aluminum Sheet Products segment includes reducing reroll coil to specific gauge, annealing, slitting, and custom coating. This segment?s products are used in customer end-use applications comprising window screen fr ames and screens, exterior home trim, fascias, roof edgings, soffits, downspouts, and gutters in the building and construction markets, as well as capital goods and transportation markets. The company offers its products to original equipment manufacturers and distributors through direct and indirect sales groups primarily in the United States, Mexico, Canada, Asia, and Europe. Quanex Building Products Corporation is based in Houston, Texas.

Advisors' Opinion:

• [By Seth Jayson]

  When judging a company's prospects, how quickly it turns cash outflows into cash inflows can be just as important as how much profit it's booking in the accounting fantasy world we call "earnings." This is one of the first metrics I check when I'm hunting for the market's best stocks. Today, we'll see how it applies to Quanex Building Products (NYSE: NX  ) .

• [By Seth Jayson]

  Quanex Building Products (NYSE: NX  ) reported earnings on June 7. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended April 30 (Q2), Quanex Building Products beat expectations on revenues and missed expectations on earnings per share.

• [By Rich Smith]

  On Tuesday, Ingersoll named Quanex Building Products (NYSE: NX  ) CEO David�D. Petratis as the new chairman, president, and CEO of its soon-to-spin-off Allegion subsidiary. Petratis has served as chairman, president, and CEO of Houston-based Quanex since July 2008.

Top 10 Solar Companies To Watch In Right Now: Exponent Inc.(EXPO)

Exponent, Inc., together with its subsidiaries, provides engineering and scientific consulting services worldwide. Its services include analysis of products, people, property, processes, and finances related to litigation, product recall, regulatory compliance, research, development, and design. The company offers approximately 90 different technical disciplines to solve complicated issues facing industry and government. It offers services in the areas of biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, defense technology development, ecological and biological sciences, electrical engineering and computer science, engineering management consulting, environmental and earth sciences, health sciences, human factors, industrial structures, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, statistical and data sciences, thermal sciences, and vehicle analysis. The compa ny provides its services through a team of scientists, physicians, engineers, and business and regulatory consultants. It serves clients in automotive, aviation, chemical, construction, consumer products, energy, government, health, insurance, manufacturing, and technology sectors. The company was formerly known as The Failure Group, Inc. and changed its name to Exponent, Inc. in 1998. Exponent, Inc. was founded in 1967 and is based in Menlo Park, California.

Advisors' Opinion:

• [By Seth Jayson]

  Calling all cash flows
  When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Exponent (Nasdaq: EXPO  ) , whose recent revenue and earnings are plotted below.

Best Up And Coming Companies To Watch In Right Now: NuVasive Inc.(NUVA)

NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedures for the spine. The company?s products focus on applications for spine fusion surgery. It offers products primarily for the thoracolumbar spine and cervical spine. The company?s principal products include a minimally disruptive surgical platform called Maximum Access Surgery (MAS), as well as cervical, biologics, and motion preservation products. Its MAS platform combines four categories of product offerings, including NVM5 and NVJJB, its proprietary software-driven nerve monitoring systems; MaXcess system that provides access to the spine with minimal soft tissue disruption; specialized implants that are used for interbody disc height restoration for fusion and stabilization of the spine, as well as biologic products comprising FormaGraft, a collagen-based synthetic bone substitute and Osteocel Plus, an allograft cellular ma trix. Its biologic products also comprise AttraX, a synthetic bone graft material; and Triad, an allograft cellular matrix containing viable mesenchymal stem cells. In addition, the company offers a range of bone allograft in patented saline packaging; disposables and spine implants under the CoRoent brand name; and fixation devices, such as rods, plates, and screws. Further, it provides intra-operative monitoring services for insight into the nervous system during spine and other surgeries. Additionally, the company is developing total disc replacement devices for lateral lumbar spine and cervical spine applications. NuVasive, Inc. sells its products through directly-employed sales shareowners, independent sales agents, and distributors to surgeons and hospitals in the United States and internationally. The company was founded in 1997 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By Bryan Murphy]

  It may not be as big as NuVasive, Inc. (NASDAQ:NUVA), and it might not be as sexy as MiMedx Group Inc. (NASDAQ:MDXG). But, Bacterin International Holdings Inc. (NYSEMKT:BONE) offers something to investors that MDXG and NUVA don't - can't - right now... a distinct opportunity for a lot of upside in a short amount of time.

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Wednesday’s session are Bank of America Corp.(BAC), Chelsea Therapeutics International Ltd.(CHTP) and NuVasive Inc.(NUVA)

Best Up And Coming Companies To Watch In Right Now: Ritchie Bros. Auctioneers Incorporated(RBA)

Ritchie Bros. Auctioneers Incorporated, an industrial auctioneer, sells various equipment to on-site and online bidders. The company, through unreserved public auctions, sells a range of used and unused industrial assets, including equipment, trucks, and other assets utilized in the construction, transportation, agricultural, material handling, mining, forestry, petroleum, and marine industries. It also provides Internet bidding services, which facilitate customers access to live and online auction participation. The company primarily serves buyers and sellers of equipment, trucks, and other industrial assets; rental companies and brokers; finance companies; and truck and equipment dealers. As of December 31, 2011, it operated approximately 110 locations in approximately 25 countries, including 43 auction sites worldwide. The company was founded in 1963 and is headquartered in Burnaby, Canada.

Advisors' Opinion:

• [By Canadian Value]

  Australians will remember 2013 in part for the fall of some of our national corporate icons. The Ford Falcon and Holden Commodore are unlikely to be produced domestically going forward, and Qantas has unsuccessfully sought subsidies from the Federal government. Due to elevated cost structures and a high exchange rate, Australia Inc. is increasingly unable to compete in a fiercely competitive global market.High on the Reserve Bank of Australia�� (RBA) Christmas wish-list this year will be a lower exchange rate and a business community more willing to loosen its purse strings in 2014. Unfortunately, the first wish will likely need to be granted before the second can be realized. We expect the RBA will need to keep policy accommodative over the cyclical horizon and 2014 will be a critical transition year for the Australian economy.Over the year through September 2013, real growth in business investment outside the mining sector slowed to almost zero (0.5% to be precise, as shown in Figure 1). Why has Australia Inc. invested so little into its businesses this year? As RBA Deputy Governor Philip Lowe commented in a speech in late October, the lack of business investment in recent years is actually a global phenomenon across the developed world.�Although hard to quantify, this ��nvestment drought,��as Lowe described it, has likely been influenced by a lingering risk aversion after the financial crisis as well as the political uncertainty that has been common in many developed countries over the past few years. But in Australia another variable has also been restraining non-mining capital expenditure, and that is the elevated exchange rate.As Figure 1 shows, changes in the real trade-weighted exchange rate have historically led changes in non-mining business investment. As the real exchange rate appreciates, domestic products and services become less competitive relative to foreign goods and services, both at home and abroad. And of course, the reverse is true w

• [By Chris Hill]

  Caterpillar's (NYSE: CAT  ) �first-quarter profit�fell 45% and the company lowered guidance. But its CEO said that his confidence is at a two-year high and sales in China rose. Should investors buy the stock? In this installment, our analysts discuss Caterpillar's future and explain why Ritchie Bros. Auctioneers (NYSE: RBA  ) could be a hidden winner.

Best Up And Coming Companies To Watch In Right Now: AstraZeneca PLC (AZN)

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.

Cardiovascular

The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.

Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.

Gastrointestinal

AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.

Infection

The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.

Neuroscience

AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).

Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.

Oncology

AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.

Advisors' Opinion:

• [By Max Macaluso, Ph.D. and David Williamson]

  In this video, health-care analysts David Williamson and Max Macaluso discuss how two Big Pharma companies --�Novo Nordisk (NYSE: NVO  ) and AstraZeneca� (NYSE: AZN  ) -- might become the next major players in the obesity space. (NYSE: AZN  )

• [By Jake L'Ecuyer]

  AstraZeneca PLC (NYSE: AZN) shares were also up, gaining 13.95 percent to $78.24 following the rejection of Pfizer's (NYSE: PFE) $76.62 per share bid.

Best Up And Coming Companies To Watch In Right Now: SWS Group Inc.(SWS)

SWS Group, Inc., a diversified financial services holding company, provides a range of investment and commercial banking, and related financial services to individual, corporate, and institutional investors, as well as broker/dealers, governmental entities, and financial intermediaries in the United States. It operates in four segments: Clearing, Retail, Institutional, and Banking. The Clearing segment provides clearing and execution services for general securities broker/dealers, bank affiliated firms, and firms specializing in high volume trading. The Retail segment offers retail securities products and services, such as equities, mutual funds, and fixed income products; insurance products; and managed accounts. The Institutional segment provides securities lending, investment banking and public finance, fixed income sales and trading, proprietary trading, and agency execution services to institutional customers. The Banking segment offers various banking products and se rvices, including certificates of deposit, money market accounts, interest-bearing demand accounts, savings accounts, federal home loan bank advances, federal funds purchased, and non interest-bearing demand accounts, as well as one to four family residential loans and construction loans, lot and land development loans, commercial real estate loans, multi family loans, commercial loans, and consumer loans. SWS Group, Inc. was founded in 1972 and is headquartered in Dallas, Texas.

Advisors' Opinion:

• [By Lauren Pollock]

  Hilltop Holdings Inc.(HTH) offered to buy the rest of SWS Group Inc.(SWS) that it doesn’t already own, valuing the financial-services company at about $231 million. Hilltop, a regional banking and insurance company, offered $7 a share, a 16% premium over Thursday’s close. SWS surged 19% to $7.20 premarket,�topping the offer price.

• [By Tim Melvin]

  SWS Group (SWS) also catches my eye at the current valuation. The Dallas-based company is in the brokerage, investment banking and banking business in the Southwest. They struggled with losses at the banking subsidiary and eventually had to find a capital infusion. They ended up borrowing $100 million from noted investors Gerald Ford and Robert Bass. The core brokerage and investment banking business are well positioned and should do well over the next few years. I wouldn�� be shocked if this firm was eventually sold off, with Mr. Ford keeping the banking assets and selling the brokerage and I-Bank units to a larger firm. With the stock trading at just 65% of book value, the long-term potential is very high for this stock.

Best Up And Coming Companies To Watch In Right Now: XOMA Ltd.(XOMA)

XOMA Ltd., a biopharmaceutical company, engages in the discovery, development, and manufacture of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. Its products under development include gevokizumab, an anti-inflammatory monoclonal antibody that inhibits interleukin-1 beta and has completed Phase 2 development stage for the treatment of Behcet?s uveitis, as well as is in Phase 2b clinical trail for Type 2 diabetes with cardiovascular biomarkers; XOMA 3AB, a biodefense anti-botulism product candidate comprising a combination or cocktail of antibodies for the treatment of botulism poisoning; and preclinical antibody discovery programs in various indications, including autoimmune, cardio-metabolic, inflammatory, and oncological diseases. The company, through its collaboration agreement with Novartis AG, is also developing HCD122, a human anti-CD40 antagonist antibody that is in Phase 1/2 clinical trial for the treatment of B-cell mediated diseases, including malignancies and autoimmune diseases; and LFA102, which is in Phase 2 clinical trial for the treatment of hematologic tumors and other undisclosed diseases. In addition, it licenses proprietary technologies relating to bacterial expression of recombinant pharmaceutical products to biotechnology and pharmaceutical companies. The company has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; SRI International; Takeda Pharmaceutical Company Limited; Novartis AG; Arana Therapeutics Limited; Kaketsuken; Genentech, Inc.; and UCB Celltech. XOMA Ltd. was founded in 1981 and is headquartered in Berkeley, California.

Advisors' Opinion:

• [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

  XOMA Corp.(XOMA) said it swung to a loss in the fourth quarter, as an increase in operating expenses offset revenue gains. The drug developer’s losses were wider than expected by the market, sending shares down 20% to $7.54 premarket.

• [By Lisa Levin]

  XOMA (NASDAQ: XOMA) shares reached a new 52-week high of $8.61. XOMA shares have jumped 196.09% over the past 52 weeks, while the S&P 500 index has gained 25.27% in the same period.

• [By Keith Speights]

  Good omen
  Xoma Pharmaceuticals (NASDAQ: XOMA  ) reported first-quarter results on Wednesday. The company announced lower revenue compared with the same period last year, but the market didn't care. Shares surged nearly 19% on other news from Xoma.

Best Up And Coming Companies To Watch In Right Now: Powershares S & P Small Cap Energy Portfolio (PSCE)

PowerShares S&P SmallCap Energy Portfolio (the Fund) seeks investment results that correspond generally to the price and yield performance of an index called the S&P SmallCap 600 Capped Energy Index (the Underlying Index). The Underlying Index consists of common stocks of the United States energy companies that are principally engaged in the business of producing, distributing or servicing energy-related products, including oil and gas exploration and production, refining, oil services, pipeline, and solar, wind and other non-oil-based energy. The Underlying Index is compiled, maintained and calculated by Standard & Poor's Financial Services LLC (Standard & Poor's). The Fund will normally invest at least 80% of its total assets in common stocks of small-capitalization energy companies. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Underlying Index. The Fund�� investment adviser is Invesco PowerShares Capital Management LLC. Advisors' Opinion:

• [By John Udovich]

  Yesterday, small cap oil and gas stock Penn Virginia Corporation (NYSE: PVA) surged 14.84% after reporting earnings and was also rising close to 6% in�pre-market trading���meaning it might be worth taking a closer look at the small cap along with the performance of ETF peers IQ Global Oil Small Cap ETF (NYSEARCA: IOIL) and PowerShares S&P SmallCap Energy Portfolio (NASDAQ: PSCE). After all, a look at the longer term chart of Penn Virginia Corporation does not reveal a pretty picture for investors over the long haul.

Best Up And Coming Companies To Watch In Right Now: Ciber Inc (CBR)

CIBER, Inc. (CIBER) is a provider of information technology (IT), business consulting and outsourcing services. The Company is engaged in solving complex IT and business issues across industries, such as energy and utilities, telecommunications, retail, healthcare, financial services, entertainment and manufacturing. The Company operates in three segments: International, North America and IT Outsourcing. Its offerings are focused around a set of core competencies which include Application Development and Management (ADM), Enterprise Resource Planning (ERP), Customer Relationship Management, Business Intelligence and Data Warehousing, Managed Services, Testing and Quality Assurance, Mobility Services and Digital Marketing. On March 9, 2012, the Company sold its Federal division to CRGT, Inc.

International

The Company�� CIBER International division delivers a mix of ERP and custom ADM solutions. CIBER International offers a range of services covering the IT solution lifecycle to both commercial enterprises and public sector organizations. Key geographies for its International division include the Netherlands, the United Kingdom, Germany and the Scandinavian region consisting of Norway, Sweden and Denmark. The International division's enterprise solutions focus primarily on providing services related to ERP and Customer Relationship Management (CRM) software products, as well as managed services. It also provides SAP Industry Solutions, such as retail, automotive and chemicals, and it is a value-added reseller of SAP software in some international geographies. Th Company works with Microsoft to deliver ERP and CRM solutions in selected international geographies.

North America

The Company�� North America division was formed during the year ended December, 31, 2011, through the combination of its former Custom Solutions division and substantially all of its former U.S. ERP division. Its North America division is organized by and operates in a matrix! of geographies and practices. Its North America division provides ADM services, IT Strategy and Architecture, Business Intelligence/Data Warehousing, Collaborative Solutions, CRM and Supply Chain. The division also offers consulting services to support multi-package ERP solutions from vendors, including Oracle (including E-Business Suite, PeopleSoft and JD Edwards), SAP and Lawson, as well as several education management products. It is focused on industry solutions for vertical markets, such as telecommunications, healthcare, manufacturing, financial services, technology, state and local governments, higher education and entertainment.

The Company designs and develops custom-tailored offerings to suit its client's business needs. Its custom solutions provide a range of application portfolio management support, including analysis, design, development, testing, implementation, outsourcing and maintenance of business applications. Its service-oriented architectures, including J2EE and .NET, as well as traditional client/server and mainframe development. The Company also offers portal development, wireless and mobility applications and content delivery. The North America division is an Oracle Platinum Partner, which is a partnership in the Oracle Partner Network Specialized Program and a strategic partner to Oracle in several key industries, such as the public sector, higher education and food and beverage. Its Oracle, PeopleSoft and JD Edwards solutions involve building, integrating and supporting mission critical systems for real-time enterprises.

The Company�� North America division also is an SAP-certified global provider of application management services. The division's SAP solutions support their customers throughout the life cycle and include implementations and upgrades, extensions, integrations and customizations. The North America division has organized its SAP Practice to serve multiple vertical markets. In its SAP Commercial Practice, the North America division foc! uses on c! ustomers in retail, apparel and footwear, mining, metals, manufacturing, financial services and aerospace and defense industries. In its SAP Public Sector Practice, the North America division focuses on delivering solutions to state and local governments.

The North America division is a Certified Lawson Consulting Partner, providing business transformation projects in Lawson's target vertical markets through business process, change management and functional and technical services around Lawson technology. These target markets are healthcare, public sector, food and beverage and general manufacturing, for which it offers budgeting, financial processing and analysis, human capital management, sales order processing and manufacturing systems solutions.

IT Outsourcing

The Company�� IT Outsourcing division is a global business with domestic headquarters in Edison, New Jersey, and international presence throughout Europe. The division offers outsourced enterprise infrastructure management solutions, including managed hosted infrastructure, end user service desk and desktop services, remote infrastructure management (RIM) and application operations support. The IT Outsourcing division's data centers, service desk centers and global operations are located in the United States, United Kingdom, Poland, India and Spain. The division's Technology Solutions Group Practice focuses on providing customers with the infrastructure products and architecture. Offerings include enterprise servers, storage, middleware, integration services, assessments and related products required to support critical business applications.

The Company competes with Accenture plc, Cognizant Technology Solutions Corp, Infosys Technologies Limited, Perficient, Inc., Sapient Corp and The Hackett Group, Inc.

Advisors' Opinion:

• [By Seth Jayson]

  Ciber (NYSE: CBR  ) is expected to report Q2 earnings on July 30. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Ciber's revenues will drop -4.8% and EPS will grow from $0.00 per share the prior year.